LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Jefferies Downgrades Astellas Pharma to Hold From Buy, Adjusts Price Target to 1,700 Yen From 2,100 Yen MT
Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer CI
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos MT
Malin Corp investee signs agreement with Astellas Pharma AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024 CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024 CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Astellas Pharma Inc. Announces Board and Committee Retirements CI
European Commission Approves Astellas Pharma Label Extension for Xtandi MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs CI
Lupin Launches Mirabegron Extended-Release Tablets in US MT
Japan Inc makes a renewed U.S. push as China fears mount RE
Middle East Tensions Blunt Asian Stock Markets Excepting China MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment RE
Chart Astellas Pharma Inc.
More charts
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,636 JPY
Average target price
1,825 JPY
Spread / Average Target
+11.54%
Consensus
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. News Astellas Pharma Inc.
  5. Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy